Advertisement
Advertisement
U.S. Markets open in 3 hrs 26 mins
Advertisement
Advertisement
Advertisement
Advertisement

Cybin Inc. (CYBN.NE)

NEO - NEO Real Time Price. Currency in CAD
0.5100-0.0400 (-7.27%)
At close: 03:59PM EST
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.5500
Open0.5700
Bid0.5000 x 0
Ask0.5700 x 0
Day's Range0.5100 - 0.5700
52 Week Range0.5000 - 1.9400
Volume177,302
Avg. Volume120,473
Market Cap81.784M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.2590
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    Cybin Inc. Presents CYB003 Preclinical Data at Neuroscience 2022

    TORONTO, November 15, 2022--Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics®, today announced that the Company presented a poster highlighting preclinical data for its deuterated psilocybin analog, CYB003 at Neuroscience 2022 hosted by the Society for Neuroscience ("SFN") taking place November 12-16, 2022, in San Diego, CA.

  • Business Wire

    Cybin Inc. Reports Second Quarter Financial Results and Recent Business Highlights

    TORONTO, November 14, 2022--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics®, today reported unaudited financial results for its second quarter ended September 30, 2022, and recent business highlights.

  • Business Wire

    Cybin Provides Progress Update on its CYB004-E Phase 1 Trial

    TORONTO, November 10, 2022--Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics®, is pleased to announce that its CYB004-E Phase 1 trial evaluating N,N-dimethyltryptamine ("DMT") has completed dosing for four out of five participant cohorts and The Safety Review Committee has confirmed no clinically significant safety or tolerability issues. The CYB004-E Phase 1 trial was acquired from Entheon Biom

Advertisement
Advertisement